Bioceres Crop Solutions Corp. (BIOX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 6-K for Q2 FY2026, filed Mar 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BIOX SEC filings page.
Bioceres Crop Solutions Corp. (BIOX) reported $294.4M in revenue over the twelve months to Dec 31, 2025, down 26.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Bioceres’ cash conversion held up through a revenue shock, while working capital tightened and accounting earnings turned sharply negative.
The unusual split in FY2025 is that net income was-$58.8M while operating cash flow reached$49.9M , pointing to noncash or timing effects rather than a cash-cost equivalent to the reported loss. The simultaneous reduction in inventory and receivables, alongside a27.9% revenue contraction, indicates cash generation was partly supported by working-capital release rather than expanding sales.
Revenue contracted sharply in FY2025 while net profit margin swung from
The 0.9x current ratio means current liabilities exceeded current assets at FY2025, a tighter short-term funding posture than FY2024’s 1.2x. Despite
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Bioceres Crop Solutions Corp.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Bioceres Crop Solutions Corp., and counted as zero in the overall score.
Bioceres Crop Solutions Corp.'s revenue declined 27.9% year-over-year, from $464.8M to $335.1M. This contraction results in a growth score of 9/100.
Bioceres Crop Solutions Corp. carries a low D/E ratio of 0.03, meaning only $0.03 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 85/100, indicating a strong balance sheet with room for future borrowing.
Bioceres Crop Solutions Corp.'s current ratio of 0.91 is below the typical benchmark, resulting in a score of 15/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Bioceres Crop Solutions Corp. has a free cash flow margin of 13.2%, earning a moderate score of 60/100. The company generates positive cash flow after capital investments, but with room for improvement.
Not available for Bioceres Crop Solutions Corp., and counted as zero in the overall score.
Bioceres Crop Solutions Corp. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Bioceres Crop Solutions Corp. reported a net loss of $58.8M while generating $49.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Bioceres Crop Solutions Corp. generated $73.8M in revenue in Q2 2026. This represents a decrease of 25.3% from the same quarter a year earlier. Against the prior quarter it is down 4.9%.
Bioceres Crop Solutions Corp. reported -$182.5M in net income in Q2 2026. This represents a decrease of 30248.2% from the same quarter a year earlier. Against the prior quarter it is down 2349.8%.
Bioceres Crop Solutions Corp. earned -$0.08 per diluted share (EPS) in Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Bioceres Crop Solutions Corp. generated $17.4M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 352.8% from the same quarter a year earlier. Against the prior quarter it is up 26.8%.
Bioceres Crop Solutions Corp. held $11.1M in cash against $8.1M in long-term debt as of Q2 2026, with $328.6M of liabilities due within a year.
Not reported for Q2 2026.
Margins & Returns
Bioceres Crop Solutions Corp.'s ROE was -171.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 171.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 168.6 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Bioceres Crop Solutions Corp. invested $12K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 99.2% from the same quarter a year earlier. Against the prior quarter it is down 98.1%.
Not reported for Q2 2026.
Not reported for Q2 2026.
BIOX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'266-K | Q1'266-K | Q4'256-K | Q3'256-K | Q2'256-K | Q1'256-K | Q4'2420-F | Q3'246-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $73.8M-25.3% | $77.6M-16.8% | $82.4M-33.5% | $60.6M-27.9% | $98.8M-29.5% | $93.3M-20.0% | $124.0M+15.5% | $84.0M-9.2% |
| Interest Expense | $8.0M+23.7% | $9.1M+27.3% | $9.1M+12.0% | $6.1M-15.6% | $6.4M+68.5% | $7.2M-6.5% | $8.2M-71.1% | $7.2M+231.8% |
| Income Tax | $3.1M+388.8% | $2.1M+264.5% | $5.9M+246.7% | -$4.0M-319.1% | $636K-92.4% | -$1.3M-395.2% | -$4.0M-155.5% | -$956K+81.6% |
| Net Income | -$182.5M-30248.2% | -$7.4M-20.2% | -$51.7M-4827.8% | -$1.6M-116.3% | $605K-51.1% | -$6.2M-131.4% | -$1.0M+62.4% | $9.8M-64.4% |
| EPS (Basic) | -$0.08-180.5% | N/A | N/A | N/A | $0.10 | N/A | N/A | N/A |
| EPS (Diluted) | -$0.08 | N/A | N/A | N/A | $0.10 | N/A | N/A | N/A |
| Diluted Shares (Avg) | N/A | 63M+0.9% | N/A | 63M-6.0% | 63M-1.1% | 63M0.0% | N/A | 67M+5.8% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA.
BIOX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'266-K | Q1'266-K | Q4'256-K | Q3'256-K | Q2'256-K | Q1'256-K | Q4'2420-F | Q3'246-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $560.4M-32.9% | $734.9M-11.2% | $763.6M-10.4% | $798.2M-4.5% | $835.2M+1.9% | $827.3M+0.9% | $852.5M+4.2% | $836.1M-1.3% |
| Current Assets | $294.3M-23.1% | $283.2M-24.9% | $308.3M-24.6% | $338.2M-16.9% | $382.6M-2.4% | $377.1M-4.6% | $408.7M+2.9% | $407.2M-3.3% |
| Cash & Equivalents | $11.1M-62.1% | $15.5M-52.0% | $32.7M-26.5% | $38.5M+135.0% | $29.2M+19.6% | $32.3M+13.8% | $44.5M-7.6% | $16.4M-71.7% |
| Inventory | $64.8M-36.4% | $88.6M-24.7% | $87.6M-30.4% | $92.0M-28.8% | $101.8M-17.7% | $117.7M-14.8% | $125.9M-10.3% | $129.2M-14.4% |
| Accounts Receivable | N/A | $158.4M-19.1% | $165.9M-20.0% | $187.5M-11.2% | $226.5M+13.4% | $195.8M+5.1% | $207.3M+31.2% | $211.2M+34.4% |
| Goodwill | $36.1M-67.8% | $112.2M0.0% | $112.2M0.0% | $112.2M0.0% | $112.2M0.0% | $112.2M0.0% | $112.2M0.0% | $112.2M-8.5% |
| Total Liabilities | $453.7M-7.2% | $446.5M-7.2% | $468.4M-6.5% | $453.2M-7.0% | $488.9M+1.0% | $481.2M-1.2% | $501.2M+2.8% | $487.6M-4.9% |
| Current Liabilities | $328.6M+13.8% | $299.7M+1.3% | $338.0M+2.6% | $332.3M-0.2% | $288.8M-8.8% | $295.9M-5.1% | $329.3M+10.2% | $333.0M+10.0% |
| Non-Current Liabilities | $125.1M-37.5% | $146.8M-20.8% | $130.4M-24.1% | $120.9M-21.8% | $200.1M+19.5% | $185.4M+5.7% | $171.9M-9.0% | $154.6M-26.3% |
| Long-Term Debt | $8.1M-25.2% | $12.8M-17.8% | $9.5M+16.7% | $10.9M+23.9% | $10.8M+13.2% | $15.5M+68.4% | $8.2M-18.6% | $8.8M-17.5% |
| Total Equity | $106.6M-69.2% | $288.3M-16.7% | $295.2M-16.0% | $345.0M-1.0% | $346.3M+3.3% | $346.0M+4.0% | $351.4M+6.3% | $348.5M+4.3% |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Retained Earnings.
BIOX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'266-K | Q1'266-K | Q4'256-K | Q3'256-K | Q2'256-K | Q1'256-K | Q4'2420-F | Q3'246-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $17.4M+424.6% | $14.4M+178.8% | $26.8M+15.1% | $23.3M+234.2% | -$5.4M-125.4% | $5.2M-65.0% | $23.3M+373.9% | -$17.4M-893.0% |
| Capital Expenditures | -$12K-99.2% | $672K-47.4% | $431K-78.6% | $2.4M+41.8% | $1.5M-27.2% | $1.3M-67.9% | $2.0M-50.1% | $1.7M-51.3% |
| Free Cash Flow | $17.4M+352.8% | $13.7M+253.4% | $26.3M+24.0% | $20.9M+209.6% | -$6.9M-136.1% | $3.9M-63.9% | $21.2M+269.5% | -$19.1M-1366.0% |
| Investing Cash Flow | -$2.8M+47.9% | -$1.3M-565.1% | $1.5M+603.7% | -$2.5M-82.6% | -$5.4M+70.7% | $272K+103.1% | -$295K+90.9% | -$1.4M+58.0% |
| Financing Cash Flow | -$18.0M-377.4% | -$28.7M-52.7% | -$25.7M-583.2% | -$12.7M-216.4% | $6.5M+828.3% | -$18.8M+30.3% | $5.3M+60.1% | $10.9M+201.7% |
| Dividends Paid | N/A | N/A | $0 | $0-100.0% | N/A | N/A | $0 | $23K |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Share Buybacks.
BIOX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'266-K | Q1'266-K | Q4'256-K | Q3'256-K | Q2'256-K | Q1'256-K | Q4'2420-F | Q3'246-K |
|---|---|---|---|---|---|---|---|---|
| Net Margin | -247.2% | -9.6%-3.0pp | -62.7%-61.8pp | -2.6%-14.3pp | 0.6%-0.3pp | -6.6%-4.3pp | -0.9%+1.7pp | 11.6%-18.1pp |
| Return on Equity | -171.2%-171.3pp | -2.6%-0.8pp | -17.5%-17.2pp | -0.5%-3.3pp | 0.2%-0.2pp | -1.8%-1.0pp | -0.3%+0.5pp | 2.8%-5.4pp |
| Return on Assets | -32.6%-32.6pp | -1.0%-0.3pp | -6.8%-6.6pp | -0.2%-1.4pp | 0.1%-0.1pp | -0.8%-0.4pp | -0.1%+0.2pp | 1.2%-2.1pp |
| Current Ratio | 0.90-0.4x | 0.94-0.3x | 0.91-0.3x | 1.02-0.2x | 1.32+0.1x | 1.270.0x | 1.24-0.1x | 1.22-0.2x |
| Debt-to-Equity | 0.080.0x | 0.040.0x | 0.030.0x | 0.030.0x | 0.030.0x | 0.040.0x | 0.020.0x | 0.030.0x |
| Asset Turnover | 0.130.0x | 0.110.0x | 0.110.0x | 0.080.0x | 0.12-0.1x | 0.110.0x | 0.150.0x | 0.100.0x |
| FCF Margin | 23.5%+30.5pp | 17.7%+13.5pp | 31.9%+14.8pp | 34.5%+57.3pp | -7.0%-20.5pp | 4.2%-5.1pp | 17.1%+28.8pp | -22.7%-21.3pp |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Note: The current ratio is below 1.0 (0.91), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Bioceres Crop Solutions Corp. BIOX | FY2025 | $335.1M | -$58.8M | -17.6% | $21.8M | 28/100 |
| American Vanguard Corporation AVD | FY2025 | $515.1M | -$49.9M | -9.7% | $51.3M | 24/100 |
| Intrepid Potash, Inc IPI | FY2025 | $298.3M | $11.2M | 3.8% | $440.8M | 52/100 |
| ENLIGHTIFY INC ENFY | FY2025 | $75.3M | -$15.6M | -20.7% | $5.8M | — |
| Origin Agritech Limited SEED | FY2025 | $12.8M | -$7.5M | -58.4% | $9.0M | 7/100 |
Where Bioceres Crop Solutions Corp. Ranks
Frequently Asked Questions
What is Bioceres Crop Solutions Corp.'s annual revenue?
Bioceres Crop Solutions Corp. (BIOX) reported $335.1M in total revenue for fiscal year 2025. This represents a -27.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bioceres Crop Solutions Corp.'s revenue growing?
Bioceres Crop Solutions Corp. (BIOX) revenue declined by 27.9% year-over-year, from $464.8M to $335.1M in fiscal year 2025.
Is Bioceres Crop Solutions Corp. profitable?
No, Bioceres Crop Solutions Corp. (BIOX) reported a net income of -$58.8M in fiscal year 2025, with a net profit margin of -17.6%.
How much debt does Bioceres Crop Solutions Corp. have?
As of fiscal year 2025, Bioceres Crop Solutions Corp. (BIOX) had $32.7M in cash and equivalents against $9.5M in long-term debt.
What is Bioceres Crop Solutions Corp.'s net profit margin?
Bioceres Crop Solutions Corp. (BIOX) had a net profit margin of -17.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Bioceres Crop Solutions Corp.'s return on equity (ROE)?
Bioceres Crop Solutions Corp. (BIOX) has a return on equity of -19.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Bioceres Crop Solutions Corp.'s free cash flow?
Bioceres Crop Solutions Corp. (BIOX) generated $44.3M in free cash flow during fiscal year 2025. This represents a 38.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Bioceres Crop Solutions Corp.'s operating cash flow?
Bioceres Crop Solutions Corp. (BIOX) generated $49.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Bioceres Crop Solutions Corp.'s total assets?
Bioceres Crop Solutions Corp. (BIOX) had $763.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Bioceres Crop Solutions Corp.'s capital expenditures?
Bioceres Crop Solutions Corp. (BIOX) invested $5.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Bioceres Crop Solutions Corp.'s current ratio?
Bioceres Crop Solutions Corp. (BIOX) had a current ratio of 0.91 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Bioceres Crop Solutions Corp.'s debt-to-equity ratio?
Bioceres Crop Solutions Corp. (BIOX) had a debt-to-equity ratio of 0.03 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bioceres Crop Solutions Corp.'s return on assets (ROA)?
Bioceres Crop Solutions Corp. (BIOX) had a return on assets of -7.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Bioceres Crop Solutions Corp.'s P/E ratio?
Bioceres Crop Solutions Corp. (BIOX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to December 31, 2025). The market capitalization is $21.8M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Bioceres Crop Solutions Corp.'s price-to-sales ratio?
Bioceres Crop Solutions Corp. (BIOX) trades at 0.1x sales, its market capitalization divided by revenue of $294.4M revenue, trailing 12 months to December 31, 2025. The market capitalization is $21.8M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Bioceres Crop Solutions Corp.'s Piotroski F-Score?
Bioceres Crop Solutions Corp. (BIOX) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bioceres Crop Solutions Corp.'s earnings high quality?
Bioceres Crop Solutions Corp. (BIOX) reported a net loss of $58.8M while generating $49.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Bioceres Crop Solutions Corp.?
Bioceres Crop Solutions Corp. (BIOX) scores 28 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.